King Abdullah International Medical Research Center is pleased to invite you to attend the Science Day: Diabetes Research & Development on May 9th, 2017 at 8:30 am at KAIMRC Building Auditorium.
The science day is a research event dedicated to presenting and discussing the latest developments in one of KAIMRC R&D focus areas and come up with recommendations on how to strengthen research in this area and develop the selected R&D program further.
The Diabetes Science Day of KAIMRC aims to explore collaborative Research opportunities, contribute to the development of the diabetes research program and clinical trials.
|8:00 –9:00||Registration & refreshments|
|8:30 – 9:00||Welcoming Remarks By KAIMRC Executive Director||Dr. Ahmed Alaskar|
|Introduction / message from the CEO|
|9:00 – 9:25|
|9:25 – 9:45||Diabetes Burden “Review “||Dr. Ali AlQarni|
|9:45 – 10:05||Molecular and cellular mechanism underlying reversal of T2D following Bariatric surgery: study using proteomic and gene chip analysis||Dr. Abderrezak Bouchama|
|10:05-10:25||RC12/150 A case-control study of the effect of lifestyle factors on the risk of type 2 diabetes in Saudi Arabia||Dr. Mustafa Al Zoughool|
|10:45 – 11:00|
|11:00 – 11: 25||Measuring the difference effects of routine managed care versus continuous quality improvement for type 2 diabetic patients in primary health care in KSA||Dr. Abdulaziz Othman Alg|
|11:25 – 11:45||The Effects of intensity dose-response of combined aerobic and resistance training on glycemic control for patients with history of type 2 diabetes.||Prof. Saleh Falah Al-Oraibi|
|11:45 – 12:15||Verifying Insulin Strategy and Initial Health Outcome Analysis||Dr. Reem Al Amoudi|
|12:15 – 12:35|
|13:35 – 13:55||RC12/083/R Isolation, and Identification the Components of the B-Cell Lymphoma Protein Complex (BCL10 Complex), and its Role in Lymphoma, Obesity, Insulin Resistance and Type II Diabetes||Dr. Ayman Saleh|
|13:55 – 14:15||RC16/201Genetic Architecture of Type 1 Diabetes (T1D) in Saudi Families with Multiple Affected Siblings||Dr. Atia Sheereen|
|14:15-14:35||A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination with Insulin)||Dr. Ibrahim Al Alwan|
For more inquiry, please do not hesitate to contact our coordinator Ms. Lamia Mouyes at direct line +966-11-42-94369 or via email: KAIMRC-ScienceDay@NGHA.MED.SA
We look forward to welcoming you to the science day and to your active participation to ensure a successful event.
Click here to view more details